Pioneering Stable and Non-Hallucinogenic Psilocin Formulations for Neurodegenerative Diseases
Haim Pharma Group (HPG) is an Israel-based virtual drug development company, advancing stabilized synthetic psilocin as a first-in-class therapy for neurodegenerative diseases. The company’s lead focus is amyotrophic lateral sclerosis (ALS), with a parallel program in Parkinson’s disease (PD). HPG is pioneering an oral enteric-coated psilocin capsule Neuros…